Release Date: September 30, 2025
Expiration Date: September 30, 2026
Activity Overview
This educational activity is an archive of the live presentation held on September 7, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is directed toward WCLC attendees, including an audience of oncologists, radiologists, pulmonologists, oncology RNs/PAs/NPs, and pharmacists involved in the treatment of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss current and emerging therapeutic options for first- and second-line treatment of EGFR-mutated NSCLC
- Formulate appropriate strategies for the management of adverse effects related to EGFR targeted therapies in NSCLC
- Develop individualized treatment plans for patients with EGFR-mutant NSCLC by implementing new data and guideline-recommended strategies